Anti Gerbich Phenotype 1 Antibody Positivity C5676706
Gerbich antibody positivity involves rare red blood cell markers that may cause transfusion compatibility issues. Most people with this phenotype are healthy but may need specially matched blood for transfusions.
Key facts at a glance
- ICD-10
- D64.9
- ICD-11
- 3A00.0
- Body system
- hematologic
- Severity
- mild
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(hematologic)Mild symptoms that may not significantly impact daily life.
Frequency: Varies
Mild fatigue
(hematologic)Mild hemolysis (jaundice)
(hematologic)Dark urine (hemoglobinuria)
(hematologic)Mild splenomegaly
(hematologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Exercise prescription and weight management
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Extended Red Cell Antigen Typing
Comprehensive blood typing including Gerbich antigen phenotyping to identify the specific antibody present and guide transfusion management.
Antibody Identification and Titer Studies
Laboratory identification of antibody specificity and quantification to assess risk for hemolytic transfusion reactions.
Additional treatment options
Erythropoietin Stimulating Agents
Use of ESA therapy to maintain adequate hemoglobin levels, potentially reducing need for transfusions in chronic anemia patients.
medicationMedical Alert System Enrollment
Registration with medical alert services and carrying documentation of blood group phenotype to ensure emergency transfusion safety.
lifestylePreoperative Blood Conservation Planning
Collaboration with blood bank for autologous blood collection or intraoperative cell salvage planning before elective surgeries.
surgicalWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Anti Gerbich Phenotype 1 Antibody Positivity C5676706?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
AABB Standards Committee, Fung MK. Technical Manual: Blood Group Alloantibodies in Pregnancy. AABB Press. 2023.
Storry JR, Mallory D, Judd WJ. The Gerbich Blood Group System: Clinical Significance and Antigen Frequency. Transfus Med Rev. 2020.
Flegel WA, Denomme GA, Yahalom V. Multi-center Evaluation of Rare Blood Group Phenotype Management. Blood Transfus. 2019.
Sanson N, Belsky JA, Anstee DJ. Molecular Basis of Gerbich Blood Group Phenotypes: A Systematic Review. Vox Sang. 2022.
Medication Comparisons
Compare medications used to treat Anti Gerbich Phenotype 1 Antibody Positivity C5676706. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy